Is Beta-lactam Effectiveness Impacted by the Duration of Drug Infusion in Critically Ill Septic Patients? A Systematic Review of Clinical Pharmacokinetics Studies

Vianna, Karina Brandt 1; da Silva Junior, João Manoel 2; Gomez, David de Souza 2
1Clinical Pharmacokinetics Center, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP - Brazil
2Division of Plastic Surgery and Burns, HC FMUSP, University of São Paulo, São Paulo, SP - Brazil

Introduction

Meropenem (MEM) and piperacillin/tazobactam (PTZ) have been prescribed to septic patients with nosocomial infection caused by susceptible Gram-negative bacteria (GNB) in the intensive care unit (ICU) mainly by intermittent 0.5 h infusion. It was demonstrated that beta-lactam effectiveness against GNB is reached only up to MIC 2 mg/L after the intermittent 0.5 h infusion.

Objective

The aim of the present review was to investigate MEM and PTZ effectiveness after recommended dose regimens by comparison of intermittent 0.5 h with extended (2-4 h) and continuous infusion.

Casuistry and Methods

A systematic review of the literature was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) statement and PICO strategy:

- **PATIENT:** Septic with normal renal function
- **INTERVENTION:** MEM or PTZ
- **COMPARISON:** Infusion: intermittent, extended, continuous
- **OUTCOME:**
  1º: - PD (PTA target 100%ΔT>MIC)
  2º: - PK alterations vs healthy volunteers
  - Microbioly of isolates

A systematic search was performed on Embase and MEDLINE databases until April 2020, without restrictions of publication date or language. Outcomes were considered according to pharmacokinetic/pharmacodynamic (PK/PD) approach.

Results

**Flow Diagram According to PRISMA Statement**

**Distribution of Studies**

**PK Septic vs Healthy**

**Effectiveness by Infusion Duration (target 100%ΔT>MIC)**

Conclusion

Superiority of extended 3 h over intermittent 0.5 h infusion was demonstrated for both beta-lactam agents, MEM and PTZ. Further pharmacokinetic studies are required to clarify beta-lactam’s profile data in ICU patients undergoing the continuous infusion. It is important to highlight that an implementation of therapeutic drug serum monitoring done in real-time followed by PK/PD approach may provide clinical support for a rational individualization of therapy in septic shock to avoid mutant selection by antimicrobial resistance development and, consequently, reduce mortality of ICU septic patients.